Latest Content

Dr. Anjana Pillai says treatment depends on stage and health, with surgery, transplant, local therapy or systemic drugs to help people live longer.

An expert discusses why up to 60% of new trial sites close in year one and what this means for patient access and research supply.

It wasn’t that I never expected a breast cancer diagnosis, it was that I had never even considered a breast cancer diagnosis.

Dr. Vinayak Venkataraman recently sat down with CURE to discuss the evolving treatment landscape for gastrointestinal stromal tumors.

The U.S. FDA has granted orphan drug designation to DPTX3186, an investigational therapy being developed for gastric cancer treatment.

Bill joined the SUNRiSE-1 trial for Inlexzo, avoiding bladder removal, staying active and reaching full remission from BCG-unresponsive bladder cancer.

No diet, supplement or vaccine can take away all risk. But using proven approaches gives me a sense of control and confidence.

Emerging investigational agents may shift the current standard of care for patients with the rare sarcoma known as gastrointestinal stromal tumors.

Advances in systemic and local therapies are helping more live longer with liver cancer and move forward after treatment as survivorship becomes a key focus.

Three experts in breast surgery, medical oncology and reconstructive surgery share their insights on the importance of Breast Cancer Awareness Month.

The FDA granted fast track designation to JSKN003 in platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

Scalp cooling helped Maureen Green feel more like herself during chemotherapy, giving her control over her appearance at a time filled with fear and uncertainty.

My first oncologist got me started with positivity in my cancer journey, which I was, thankfully able to internalize.